This is a material pipeline expansion for ORKA-001 into IBD, a large and competitive market with established IL-23 blockbusters (Skyrizi, Stelara). The dosing restrictions create a clear timeline catalyst: watch for IND filings or Phase I starts in IBD after June 2028. The change-of-control acceleration clause also makes Oruka a more attractive M&A target.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $55.23entry
- T+1 · 6mo ago +3.57%α +4.26% · $57.20
- T+5 · 5mo ago +21.18%α +24.15% · $66.93
- T+20 · 5mo ago +68.91%α +70.48% · $93.29
- T+60 · 3mo ago +80.05%α +78.93% · $99.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oruka Therapeutics amended its IL-23 license agreement with Paragon Therapeutics to expand the field of use to include inflammatory bowel disease (IBD), removing a key restriction on ORKA-001's addressable market. The amendment imposes dosing restrictions (no monotherapy IBD dosing until June 2030, no combination dosing until June 2028), but these accelerate to June 2028 upon a material transaction like a change of control. This significantly expands the commercial opportunity for ORKA-001, a $3.5B market cap biotech's lead asset.
Key Facts
- Oruka expanded the field of use for its IL-23 license to include all therapeutic areas, including inflammatory bowel disease (IBD), which was previously excluded.
- Monotherapy dosing of ORKA-001 for IBD is restricted until June 1, 2030; combination dosing until June 1, 2028.
- Upon a material transaction (change of control or sale of Phase II-stage assets), the monotherapy restriction accelerates to June 1, 2028.
- Paragon granted Oruka exclusivity in the IBD field until October 11, 2029, and Oruka granted Paragon a non-exclusive cross-license for retained antibodies outside IBD.
- The amendment was signed May 29, 2026, and filed June 1, 2026.
Financial Impact
No financial terms disclosed; the amendment expands the addressable market for ORKA-001 to include IBD, a multi-billion-dollar therapeutic area.
Risk Factors
- IBD market is highly competitive with approved IL-23 inhibitors (Skyrizi, Stelara, Tremfya), ORKA-001 must differentiate on efficacy, safety, or dosing.
- Dosing restrictions delay IBD clinical development until at least 2028, limiting near-term value inflection.
- No financial consideration disclosed, the amendment's value depends entirely on ORKA-001's clinical profile in IBD, which is unproven.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063481 |
| Document: ea029287601ex10-1.htm | 0001213900-26-063481 |
| Document: 0001213900-26-063481-index-headers.html | 0001213900-26-063481 |
| Document: 0001213900-26-063481-index.html | 0001213900-26-063481 |
| Document: 0001213900-26-063481.txt | 0001213900-26-063481 |
Track record
40 reports on ORKA
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +21.13% at T+60 after the Apr 27, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers